MedTrace Logo

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

NCT06995001 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-05-29

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics and immunogenicity of a single dose of SHR-2173 by subcutaneous injection.

Conditions

  • Healthy Volunteers

Interventions

DRUG

SHR-2173

SHR-2173 injection dose 1；

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 2 ；Pacebo dose 2

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 3 ；Pacebo dose 3

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 4 ；Pacebo dose 4

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 5 ；Pacebo dose 5

Sponsors & Collaborators

  • Guangdong Hengrui Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-28
Primary Completion
2024-11-28
Completion
2024-11-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06995001 on ClinicalTrials.gov